Roy Wu - NovaBay Pharmaceuticals President
| NBY Stock | USD 0.08 0 4.28% |
President
Mr. Roy J. Wu M.B.A. is Senior Vice President Business Corporationrationrate Development of NovaBay Pharmaceuticals Inc. He has served as our Senior Vice President for Business and Corporationrationrate Development since July 2009. Prior to joining NovaBay Mr. Wu was the vice president of business development at Genelabs Technologies Inc. from 2001 to 2009 where he was responsible for all business development and licensing activities including search evaluation and contract negotiations for all in and outlicense transactions as well as alliance management and assisting in corporate financing activities. At Genelabs Mr. Wu completed numerous licensing agreements and research collaborations with companies including Novartis Gilead Sciences Tanabe Seiyaku and Affymetrix. Mr. Wus prior experience also includes serving as the vice president of Kissei Pharma USA Inc. from 1999 to 2001 where he also was responsible for clinical development regulatory affairs and business development director of business development at QuintilesBRI from 1995 to 1997 and sixteen years at Syntex where he started as a chemist and was consistently promoted until he became the director of research development and program planning management Japan since 2009.
| Age | 59 |
| Tenure | 15 years |
| Professional Marks | MBA |
| Address | 2000 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 899 8800 |
| Web | https://novabay.com |
NovaBay Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.2459) % which means that on every $100 spent on assets, it lost $0.2459. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3903) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -1.1 in 2024. At this time, NovaBay Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2 M in 2024, whereas Other Assets are likely to drop slightly above 461.6 K in 2024.Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.25 |
NovaBay Pharmaceuticals Leadership Team
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Maderis, Independent Director | ||
| Andrew Jones, Chief Financial Officer, Treasurer | ||
| David Stroman, Chair of The Ophthalmology Advisory Board and Sr. VP of Ophthalmic Product Devel. | ||
| Jason Raleigh, Chief Financial Officer, Treasurer | ||
| Lewis Stuart, Chief Commercial Officer | ||
| Jeffrey MD, Pres DERMAdoctor | ||
| Massimo Radaelli, Director | ||
| Justin Hall, President, Chief Executive Officer, Director | ||
| John McGovern, CFO, Treasurer | ||
| Thomas Paulson, CFO, Treasurer, Secretary | ||
| Mark Sieczkarek, Chairman, Interim CEO and Interim Pres | ||
| Tommy Law, Interim Controller | ||
| Xiaoyan Liu, Director | ||
| Xinzhou Li, Director | ||
| Todd Zavodnick, Director | ||
| Xiaopei Wang, Director | ||
| Lynn Christopher, Interim Chief Financial Officer and Treasurer | ||
| Roy Wu, Senior Vice President - Business & Corporate Development | ||
| Swan Sit, Independent Director | ||
| Mijia Wu, Director | ||
| Audrey MD, Chief Director | ||
| Paul Freiman, Independent Chairman of the Board | ||
| Justin Esq, CEO and President | ||
| Yenyou Zheng, Independent Director | ||
| Russell Hoon, Sr. VP of Advanced Wound Care | ||
| Yonghao Ma, Director | ||
| Wang Xu, Controller and Senior Manager | ||
| Yanbin Liu, Director |
NovaBay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NovaBay Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 3.95 M | ||||
| Shares Outstanding | 30.1 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 3.95 % | ||||
| Number Of Shares Shorted | 718.77 K | ||||
| Price To Earning | (5.43) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NovaBay Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NovaBay Pharmaceuticals' short interest history, or implied volatility extrapolated from NovaBay Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for NovaBay Stock analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.96) | Revenue Per Share 3.494 | Quarterly Revenue Growth 0.023 | Return On Assets (0.25) | Return On Equity (1.39) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.